Modotuximab

Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo[1].

Product Specifications

CAS Number

[1310460-86-6]

Product Name Alternative

DS 1024

UNSPSC

12352203

Target

EGFR

Type

Inhibitory Antibodies

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/modotuximab.html

Purity

99.08

Solubility

10 mM in DMSO

Smiles

[Namilumab]

Molecular Weight

(146.6 kDa)

References & Citations

[1]Keir ST, et al. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. J Neurooncol. 2018 Jul;138 (3) :489-498.|[2]Modotuximab. IMGT Database.